{"groups":[{"description":"Viracta (VRx)-3996: 10 mg twice daily (BID) valganciclovir: 900 mg BID","id":"FG000","title":"Phase 1b Dose Escalation Cohort 1"},{"description":"VRx-3996: 5 mg BID valganciclovir: 450 mg BID","id":"FG001","title":"Phase 1b Dose Escalation Cohort 2a"},{"description":"VRx-3996: 10 mg once daily (QD) valganciclovir: 450 mg BID","id":"FG002","title":"Phase 1b Dose Escalation Cohort 2b"},{"description":"VRx-3996: 10 mg QD valganciclovir: 900 mg QD","id":"FG003","title":"Phase 1b Dose Escalation Cohort 2c"},{"description":"VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD","id":"FG004","title":"Phase 1b Dose Escalation Cohort 3"},{"description":"VRx-3996 recommended Phase 2 dose \\[RP2D\\]: 20 mg once daily \\[QD\\] on Days 1 to 4/week) and valganciclovir 900 mg QD","id":"FG005","title":"Phase 2 Dose Expansion - Capsule"},{"description":"VRx-3996 recommended Phase 2 dose \\[RP2D\\]: 20 mg once daily \\[QD\\] on Days 1 to 4/week and valganciclovir 900 mg QD","id":"FG006","title":"Phase 2 Expansion - Tablet"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"30"},{"groupId":"FG006","numSubjects":"9"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"30"},{"groupId":"FG006","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Starting valganciclovir dosage reductions based on creatinine clearance were allowed for participants with renal impairment."}